• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Calyxt Inc.

    6/12/23 5:21:27 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials
    Get the next $CLXT alert in real time by email
    SC 13D 1 d520948dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.    )

     

     

    Cibus, Inc.

    (Name of Issuer)

    Class A Common Stock, $0.0001 per share

    (Title of Class of Securities)

    17166A 101

    (CUSIP Number)

    Jean-Pierre J. Lehmann

    c/o Cibus, Inc.

    6455 Nancy Ridge Drive

    San Diego, CA 92121

    (858) 450-0008

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    CUSIP: 17166A 101

    Page: Page 2 of 7

     

      1    

      NAME OF REPORTING PERSONS

     

      Jean-Pierre J. Lehmann

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Switzerland

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      1,687,071

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      1,687,071

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,687,071

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      9.6%(1)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Calculated using 17,601,881 shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), of Cibus, Inc., a Delaware corporation (the “Issuer”), outstanding as of May 31, 2023, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2023.

     

    - 2 -


    CUSIP: 17166A 101

    Page: Page 3 of 7

     

      1    

      NAME OF REPORTING PERSONS

     

      JPL Investments SA

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Switzerland

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      1,687,071

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      1,687,071

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,687,071

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      9.6%(1)

    14  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Calculated using 17,601,881 shares of Class A Common Stock of the Issuer outstanding as of May 31, 2023, as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on June 1, 2023.

     

    - 3 -


    CUSIP: 17166A 101

    Page: Page 4 of 7

     

    Item 1.

    Security and Issuer.

    The title and the class of equity securities to which this statement on Schedule 13D (“Schedule 13D”) relates are the shares of Class A Common Stock of the Issuer, whose principal executive offices are located at 6455 Nancy Ridge Drive, San Diego, CA 92121.

     

    Item 2.

    Identity and Background.

    (a) This Schedule 13D is filed jointly by (i) Jean-Pierre J. Lehmann and (ii) JPL Investments SA, a Swiss corporation (collectively, the “Reporting Persons”). Mr. Lehmann and Clarisse Garman serve on the board of directors of JPL Investments SA.

    (b) The principal business address of Jean-Pierre J. Lehmann is c/o Cibus, Inc. 6455 Nancy Ridge Drive San Diego, CA 92121. The principal business address of JPL Investments SA is 21 Alpinastrasse, CH 3780 Gstaad, Switzerland. The principal business address of Clarisse Garman is c/o Green Granges Again LTD, 360 Madison Avenue 9F, New York, NY 10017.

    (c) Jean-Pierre J. Lehmann is retired. The principal business of JPL Investments SA is investments in securities. Clarisse Garman is a consultant at Green Granges Again LTD, located at 360 Madison Avenue 9F, New York, NY 10017.

    (d) During the last five years, neither the Reporting Persons nor, in the case of JPL Investments SA, any of its directors has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, neither the Reporting Persons nor, in the case of JPL Investments SA, any of its directors has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Jean-Pierre J. Lehmann and Clarisse Garman are citizens of Switzerland. JPL Investments SA is a Swiss corporation.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    On May 31, 2023, the Issuer (formerly Calyxt, Inc.) (prior to the completion of the business combination, “Calyxt”) completed its business combination in accordance with the terms of the Agreement and Plan of Merger, dated as of January 13, 2023, as amended by the First Amendment thereto, dated as of April 14, 2023 (as amended, the “Merger Agreement,” and the transactions contemplated thereby, the “Transactions”), by and among Calyxt, Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt (“Merger Subsidiary”), Cibus Global, LLC, a Delaware limited liability company (“Cibus Global”), and certain blocker entities party thereto.

    Upon closing of the Transactions, Calyxt was renamed “Cibus, Inc.”, the Issuer’s Amended and Restated Certificate of Incorporation was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt’s existing common stock remained as Class A Common Stock.

    The Reporting Persons were equity holders of Cibus Global prior to the closing of the Transactions and acquired 1,687,071 shares of Class A Common Stock on May 31, 2023 as merger consideration in connection with the Transactions.

    The foregoing references to and descriptions of the Merger Agreement and Transactions do not purport to be complete and are subject to, and are qualified in their entirety by reference to, the full text of the Merger Agreement, attached hereto as Exhibits 1.01 and 1.02.

     

    Item 4.

    Purpose of Transaction.

    The information set forth in Item 3 is incorporated by reference in its entirety into this Item 4.

    Mr. Lehmann serves as a member of the board of directors of the Issuer and, in such capacity, has influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

     

    - 4 -


    CUSIP: 17166A 101

    Page: Page 5 of 7

     

    As described in Item 3 above, the Reporting Persons acquired the shares of Class A Common Stock in connection with the Transactions. The Reporting Persons presently consider the shares of Class A Common Stock as an investment and intend to review their investment on an ongoing basis, taking into account a number of factors, including, without limitation, general market and economic conditions. Such continuing review may result in the Reporting Persons acquiring additional shares of Class A Common Stock in the open market or in privately negotiated transactions, maintaining their holdings at current levels or selling all or a portion of holdings in the open market or in privately negotiated transactions. Any transactions conducted by the Reporting Persons will be subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D and the Issuer’s Insider Trading Policy.

    Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5.

    Interest in Securities of the Issuer.

    (a) As a result of the Transactions, the Reporting Persons beneficially own 1,687,071 shares of Class A Common Stock, representing approximately 9.6% of the 17,601,881 shares of Class A Common Stock outstanding as of May 31, 2023, giving effect to the 1-for-5 reverse stock split of Calyxt’s common stock on May 31, 2023 and immediately following the closing of the Transactions, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2023.

    (b) The number of shares of Class A Common Stock as to which the Reporting Persons have sole voting power, shared voting power, sole dispositive power and shared dispositive power is set forth in boxes (7), (8), (9) and (10), respectively, on the cover pages to this Schedule 13D, and such information is incorporated herein by reference. Mr. Lehmann is the President of JPL Investments SA and beneficially owns the shares of Class A Common Stock held by JPL Investments SA.

    (c) Except as described in this Schedule 13D, during the past 60 days the Reporting Persons have not effected any transactions in the shares of Class A Common Stock.

    (d) Except as disclosed in this Schedule 13D, to the knowledge of the Reporting Persons, no one other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of the Issuer reported as beneficially owned by the Reporting Persons herein.

    (e) Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Cibus Global Support Agreement

    Concurrently with the execution of the Merger Agreement and as a condition to Calyxt entering into the Merger Agreement, Calyxt entered into support agreements (the “Cibus Global Support Agreements”) with certain of Cibus Global’s equity holders, directors and officers (the “Cibus Global Supporting Unitholders”) who, collectively and in the aggregate as of January 13, 2023, held voting power of approximately 54.3% of the outstanding Cibus Global membership units (the “Subject Units”). Pursuant to the terms of the Cibus Global Support Agreements, the Cibus Global Supporting Unitholders agreed to take certain actions to support the Transactions, including not transferring the Subject Units during the term of the Cibus Global Support Agreements except under specified circumstances and voting (or acting by written consent) all of its Subject Units in favor of the Mergers and the other Transactions, against any alternative acquisition proposals and to convert all outstanding pre-closing Cibus Global preferred units into pre-closing Cibus Global voting common units on a one-for-one basis.

    The Cibus Global Support Agreements also contained customary termination provisions, including termination with respect to a given Cibus Global Supporting Unitholder in the event of any modification or amendment to the Merger Agreement in a manner that reduced the amount or changed the form of merger consideration payable to such Cibus Global Supporting Unitholder or otherwise adversely affected the Cibus Global Supporting Unitholder in any material respect without his, her or its prior written approval.

    The foregoing summary of the Cibus Global Support Agreements is not complete and is qualified in its entirety by the full text of the form of Cibus Global Support Agreement attached hereto as Exhibit 1.03 and incorporated herein by reference.

     

    - 5 -


    CUSIP: 17166A 101

    Page: Page 6 of 7

     

    Lock-Up Agreement

    On June 1, 2023, the newly appointed directors and certain officers of the Issuer entered into lock-up agreements pursuant to which they agreed, for a period of six months, not to transfer 90% of the shares of Class A Common Stock or any security convertible into or exercisable for shares of Class A Common Stock they held immediately after the closing of the Transactions, subject to customary exemptions (the “Lock-Up Agreements”).

    The foregoing summary of the Lock-Up Agreements is not complete and is qualified in its entirety by the full text of the form of Lock-Up Agreement attached hereto as Exhibit 1.04 and incorporated herein by reference.

     

    Item 7.

    Material to be Filed as Exhibits.

     

    1.01    Agreement and Plan of Merger, dated January 13, 2023, by and among Calyxt, Inc., Calypso Merger Subsidiary, LLC, Cibus Global, LLC and the other parties thereto (incorporated by reference to Exhibit 2.1 to the Issuer’s Current Report on Form 8-K filed on January 17, 2023).
    1.02    First Amendment to Agreement and Plan of Merger, dated as of April 14, 2023, by and among Calyxt, Inc. and Cibus Global, LLC (incorporated by reference to Exhibit 2.1 to the Issuer’s Current Report on Form 8-K filed on April 14, 2023).
    1.03    Form of Cibus Global Support Agreement (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on January 17, 2023).
    1.04    Form of Lock-Up Agreement (filed herewith).

     

    - 6 -


    CUSIP: 17166A 101

    Page: Page 7 of 7

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: June 12, 2023

     

    /s/ Jean-Pierre J. Lehmann
    Jean-Pierre J. Lehmann

     

    JPL INVESTMENTS SA
    By:   /s/ Jean-Pierre J. Lehmann
      Name: Jean-Pierre J. Lehmann
      Title: President

     

    - 7 -

    Get the next $CLXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLXT

    DatePrice TargetRatingAnalyst
    3/4/2022$6.00 → $4.00Buy
    Canaccord Genuity
    11/2/2021$10.00Buy
    ROTH Capital
    More analyst ratings

    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      1/3/24 7:08:08 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company

      3 - Cibus, Inc. (0001705843) (Issuer)

      9/25/23 4:49:52 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Announces Stockholder Approval of Merger With Cibus

      -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. The closing of the merger is anticipated to take place on or around Wednesday, May 31, 2023, subject to the satisfaction of the remainin

      5/19/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

      —Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement (the Merger Agreement) with Cibus Global, LLC (Cibus), a leader in precis

      5/1/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Calyxt with a new price target

      Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $4.00 from $6.00 previously

      3/4/22 8:44:27 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Calyxt with a new price target

      ROTH Capital initiated coverage of Calyxt with a rating of Buy and set a new price target of $10.00

      11/2/21 8:38:36 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Calyxt with a new price target

      Canaccord Genuity resumed coverage of Calyxt with a rating of Buy and set a new price target of $16.00

      2/22/21 7:29:33 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

      ROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSprin

      10/12/21 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Appoints Michael A. Carr as Chief Executive Officer

      ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural ingredients and renewable energy. "Michael's operational, financial, and investment experience, paired with his diverse knowledge across industries including health, nutrients, bioenergy and services will be integral as we adva

      7/15/21 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Financials

    Live finance-specific insights

    See more

    $CLXT
    SEC Filings

    See more

    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      —Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— —Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value— —Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US

      11/3/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

      ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call. The conference call will be webcast and can be accessed via the investor relations section of the Company's

      10/27/22 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Mi

      8/4/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/9/24 4:47:04 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:15:59 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 424B5 filed by Calyxt Inc.

      424B5 - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:07:41 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

      SC 13G/A - Cibus, Inc. (0001705843) (Subject)

      2/9/24 8:50:20 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Calyxt Inc.

      SC 13G - Cibus, Inc. (0001705843) (Subject)

      7/10/23 10:20:11 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D filed by Calyxt Inc.

      SC 13D - Cibus, Inc. (0001705843) (Subject)

      6/12/23 5:28:58 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials